| 摘要 |
<p>The invention resides in the use of crystalline (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-diene-20-yn-3-one (Org 30659) for the preparation of a pharmaceutical formulation which crystalline Org 30659 is in a crystal form C, having a melting point of 158.7 °C and an enthalpy ΔH of 71.9 mJ/mg which pharmaceutical formulation retains a content of Org 30659 of more than 90 % of the starting content of the pharmaceutical formulation after storage for 8 months under conditions of 40 °C and relative environmental humidity of 75 %.</p> |
